Switch theme
Sign up to access all valuation multiples
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
2017
60
LTM Revenue n/a
LTM EBITDA n/a
-$27.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Passage Bio has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Passage Bio achieved revenue of n/a and an EBITDA of -$62.1M.
Passage Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Passage Bio valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$99.3M | -$62.1M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$136M | -$102M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Passage Bio's stock price is $0.
Passage Bio has current market cap of $23.8M, and EV of -$27.5M.
See Passage Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$27.5M | $23.8M | XXX | XXX | XXX | XXX | $-0.96 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Passage Bio has market cap of $23.8M and EV of -$27.5M.
Passage Bio's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Passage Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Passage Bio and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$27.5M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | 0.4x | XXX | XXX | XXX |
| P/E | -0.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPassage Bio's NTM/LTM revenue growth is n/a
Passage Bio's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.1M for the same period.
Over next 12 months, Passage Bio's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Passage Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Passage Bio and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -37% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Passage Bio acquired XXX companies to date.
Last acquisition by Passage Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . Passage Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Passage Bio founded? | Passage Bio was founded in 2017. |
| Where is Passage Bio headquartered? | Passage Bio is headquartered in United States of America. |
| How many employees does Passage Bio have? | As of today, Passage Bio has 60 employees. |
| Who is the CEO of Passage Bio? | Passage Bio's CEO is Dr. William Chou, M.D.. |
| Is Passage Bio publicy listed? | Yes, Passage Bio is a public company listed on NAS. |
| What is the stock symbol of Passage Bio? | Passage Bio trades under PASG ticker. |
| When did Passage Bio go public? | Passage Bio went public in 2020. |
| Who are competitors of Passage Bio? | Similar companies to Passage Bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Passage Bio? | Passage Bio's current market cap is $23.8M |
| Is Passage Bio profitable? | Yes, Passage Bio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
